Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.

Content Provider	Europe PMC
Author	de Leeuw, David C. Ossenkoppele, Gert J. Janssen, Jeroen J. W. M.
Abstract	AbstractPurpose of ReviewTreatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous disease biology, and a rapidly evolving treatment landscape. Here, we highlight the importance of determining fitness, review the latest therapeutic developments, and discuss clinical scenarios to provide guidance on individualized treatment for older AML patients.Recent FindingsSeveral factors, like age, performance status, and comorbidities, play a role in fitness and are associated with outcome. Comorbidity scoring systems and geriatric assessments are tools to help physicians select the most appropriate treatment for each patient. The addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and enhanced formulas of existing drugs like CPX-351 and oral azacitidine have improved responses and outcomes.SummaryNew drugs and combination therapies have increased the therapeutic options for elderly AML patients but determination of fitness and disease biology is essential to select patient-tailored treatments.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9606099&blobtype=pdf
ISSN	15233790
Journal	Current Oncology Reports [Curr Oncol Rep]
Volume Number	24
DOI	10.1007/s11912-022-01299-9
PubMed Central reference number	PMC9606099
Issue Number	11
PubMed reference number	35653050
e-ISSN	15346269
Language	English
Publisher	Springer US
Publisher Date	2022-06-02
Publisher Place	New York
Access Restriction	Open
Rights License	Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2022
Subject Keyword	Acute myeloid leukemia Elderly Fitness Treatment Intensive chemotherapy Hematopoietic stem cell transplantation Hypomethylating agents Targeted therapy FTL3 inhibitors IDH inhibitors Venetoclax Enasidenib Ivosidenib Gilteritinib Midostaurin Gemutuzumab ozogamicin Glasdegib CPX-351 Vyxeos CC-486 Azacitidine Decitabine
Content Type	Text
Resource Type	Article
Subject	Oncology